All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
Introducing
Now you can personalise
your MDS Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the MDS Hub spoke to Virginia Volpe, Moffitt Cancer Center, Tampa, US. We asked: What is the relationship between the SF3B1 splicing mutation and therapy-related MDS?
What is the relationship between the SF3B1 splicing mutation and therapy-related MDS?
Here, Virginia Volpe discusses the similarities and differences in characteristics between patients with SF3B1 mutations and de novo MDS vs treatment-related MDS. Additionally, she compares patients harboring SF3B1 mutations vs those with wild type SF3B1 in these disease settings.
Subscribe to get the best content related to MDS delivered to your inbox